Evidence map›Paper›PMID 26696979›Full record

ArticleFrontiers in microbiology2015

Leishmanicidal Activity of Piper nigrum Bioactive Fractions is Interceded via Apoptosis In Vitro and Substantiated by Th1 Immunostimulatory Potential In Vivo.

Garima Chouhan, Mohammad Islamuddin, Muzamil Y Want, Hani A Ozbak, Hassan A Hemeg, Dinkar Sahal, Farhat Afrin

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Pathogens (Basel, Switzerland) · 2022
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Sesamol Induces Apoptosis-Like Cell Death inFrontiers in cellular and infection microbiology · 2021
    Article
  8. Review
  9. Article
  10. Molecules (Basel, Switzerland) · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Garima ChouhanParasite Immunology Laboratory, Department of Biotechnology, Faculty of Science, Jamia Hamdard (Hamdard University) New Delhi, India.
Mohammad IslamuddinParasite Immunology Laboratory, Department of Biotechnology, Faculty of Science, Jamia Hamdard (Hamdard University) New Delhi, India.
Muzamil Y WantParasite Immunology Laboratory, Department of Biotechnology, Faculty of Science, Jamia Hamdard (Hamdard University) New Delhi, India.
Hani A OzbakDepartment of Medical Laboratories Technology, Faculty of Applied Medical Sciences, Taibah University Medina, Saudi Arabia.
Hassan A HemegDepartment of Medical Laboratories Technology, Faculty of Applied Medical Sciences, Taibah University Medina, Saudi Arabia.
Dinkar SahalMalaria Research Group, International Centre for Genetic Engineering and Biotechnology New Delhi, India.
Farhat AfrinParasite Immunology Laboratory, Department of Biotechnology, Faculty of Science, Jamia Hamdard (Hamdard University) New Delhi, India ; Department of Medical Laboratories Technology, Faculty of Applied Medical Sciences, Taibah University Medina, Saudi Arabia.
Taibah University · SADepartment of Biotechnology · INInternational Centre for Genetic Engineering and Biotechnology · INJamia Hamdard · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is a life-threatening protozoal infection chiefly impinging the rural and poor population in the tropical and sub-tropical countries. The deadly affliction is rapidly expanding after its association with AIDS, swiftly defying its status of a neglected disease. Despite successful formulation of vaccine against canine leishmaniasis, no licensed vaccine is yet available for human VL, chemotherapy is in appalling state, and the development of new candidate drugs has been painfully slow. In face of lack of proper incentives, immunostimulatory plant preparations owing antileishmanial efficacy bear potential to rejuvenate awful antileishmanial chemotherapy. We have earlier reported profound leishmanicidal activity of Piper nigrum hexane (PNH) seeds and P. nigrum ethanolic (PNE) fractions derived from P. nigrum seeds against Leishmania donovani promastigotes and amastigotes. In the present study, we illustrate that the remarkable anti-promastigote activity exhibited by PNH and PNE is mediated via apoptosis as evidenced by phosphatidylserine externalization, DNA fragmentation, arrest in sub G0/G1 phase, loss of mitochondrial membrane potential and generation of reactive oxygen species. Further, P. nigrum bioactive fractions rendered significant protection to L. donovani infected BALB/c mice in comparison to piperine, a known compound present in Piper species. The substantial therapeutic potential of PNH and PNE was accompanied by elicitation of cell-mediated immune response. The bioactive fractions elevated the secretion of Th1 (INF-γ, TNF-α, and IL-2) cytokines and declined IL-4 and IL-10. PNH and PNE enhanced the production of IgG2a, upregulated the expression of co-stimulatory molecules CD80 and CD86, augmented splenic CD4(+) and CD8(+) T cell population, induced strong lymphoproliferative and DTH responses and partially stimulated NO production. PNH and PNE were devoid of any hepatic or renal toxicity. These encouraging findings merit further exploration of P. nigrum bioactive fractions as a source of potent and non-toxic antileishmanials.

Indexed as

antileishmanialapoptosisimmunomodulatoryLeishmania donovanileishmanicidalPiper nigrumVisceral leishmaniasis

Identifiers

PMID26696979
PMCPMC4672717
OpenAlexW2242382636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.